Sorafenib-resistant PDGFR mutants don't bind sorefenib

Stable Identifier
Reaction [transition]
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Sorafenib has broader effectiveness against many imatinib-resistant PDGFR mutations that sunitinib, however both D842V and S601P show resistance to inhibition by sorafenib as well (Heinrich et al, 2012; Salemi et al, 2009; reviewed in Corless et al, 2011).

Literature References
PubMed ID Title Journal Year
19210352 A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome

Salemi, S, Yousefi, S, Simon, D, Schmid, I, Moretti, L, Scapozza, L, Simon, HU

Allergy 2009
22089421 Gastrointestinal stromal tumours: origin and molecular oncology

Corless, CL, Barnett, CM, Heinrich, MC

Nat. Rev. Cancer 2011
22665524 Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors

Heinrich, MC, Mariño-Enríquez, A, Presnell, A, Donsky, RS, Griffith, DJ, McKinley, A, Patterson, J, Taguchi, T, Liang, CW, Fletcher, JA

Mol. Cancer Ther. 2012
Participant Of
Normal reaction
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Cite Us!